Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector.
about
Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methodsGene Therapy Applications to Cancer TreatmentGene therapy for carcinoma of the breast: Genetic immunotherapyCo-expression of sCD40LIg and CTLA4Ig mediated by adenovirus prolonged mouse skin allograft survival.Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells.Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathwayTargeting of adenovirus via genetic modification of the viral capsid combined with a protein bridgeChapter two--Adenovirus strategies for tissue-specific targeting.Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunityA genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivoTransductional targeting of adenovirus vectors for gene therapySampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cellsSensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator.Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens.CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation.Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responsesStrategies to overcome host immunity to adenovirus vectors in vaccine development.A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1.New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.Retargeting of viruses to generate oncolytic agents.Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma.Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subsetFunctional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapterGenome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner.Genetically targeted adenovirus vector directed to CD40-expressing cellsRecombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigensDeletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobsToward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.Development of an adenovirus vector vaccine platform for targeting dendritic cells.
P2860
Q24683349-F1284A8C-6C58-4122-AEB1-B97213660832Q24792808-25C934A6-664C-4DEB-B5B7-E2B53A6726FDQ24797848-AFFD4F7C-A87E-442D-8B92-62BD8A6361E1Q33243196-ABEFBD51-E551-47D6-94CA-A9D0C8878492Q33808695-0E999A2E-D184-4A8C-A9A8-880B67D4A31DQ33811694-82C65236-0288-4C03-B14B-9C913D55A6E9Q34226547-761A9338-EADC-451C-837B-9CE0BF1A97AEQ34643252-2117DADE-F581-494E-B03E-365430A362B9Q34648154-4EFC36E8-C2DA-4828-AA27-203C7931B537Q35005484-C6F56A73-1FAC-4693-9BE3-6FCB58DDA557Q35609035-244D1C19-AFA6-415E-987E-F98CAD98598EQ35747474-D88933E0-ABB4-427F-A90D-7D9F9E864050Q35785414-B4E3E69D-F6D8-4C65-B312-B310ACC638B8Q36315185-FA40A180-1EE4-4FF9-9A6F-5096D5F3F05DQ36622359-774892C2-6109-4B96-A8D7-08814D1E9844Q36671187-83C89EA2-6127-41FE-858B-FA07CF1FEED7Q36954135-E3A9AF9F-3AC2-4641-9136-CB8659DC2171Q37503253-D683BD1D-0484-4431-A643-F27DAD125C0DQ37647461-12F5C34C-EB1C-4D22-9130-4887C89692E1Q37820489-F5143504-3ED3-4B4C-8687-3BF1E7413EB0Q37820820-F2A99886-F597-48EB-A6CC-82D511D278BDQ37974160-88559D38-4A55-43DB-AD4F-BF94E4A063CEQ37982062-904A5B78-5885-4079-B9DD-3BC5E34B92ABQ39004228-F15691EE-B557-4A7B-95C8-E5065E73016AQ39597114-B462C149-E835-4E8B-A94D-B2F0074F306BQ39601286-1E24A3A1-273D-4E5C-B55D-1E97375E417FQ39960246-313F7E80-7E97-4BDE-9A6F-27ED28EBBA58Q40012083-786F1C68-0723-476A-98CF-FFBD8271619CQ40390251-066A6178-BA72-4C22-A12D-D5E162206579Q40722127-7EBE681C-7DC5-4FC4-875A-1047502A1918Q46429495-97B62C4D-2F56-44DF-A33F-A2B956A78FEEQ47248134-BFEB6E7C-FBB2-443D-9E96-085CA49D41E5
P2860
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Maturation of dendritic cells ...... 40-targeted adenoviral vector.
@en
type
label
Maturation of dendritic cells ...... 40-targeted adenoviral vector.
@en
prefLabel
Maturation of dendritic cells ...... 40-targeted adenoviral vector.
@en
P2093
P1476
Maturation of dendritic cells ...... 40-targeted adenoviral vector.
@en
P2093
Gerritsen WR
Luykx-de Bakker SA
Scheper RJ
Tillman BW
de Gruijl TD
P304
P407
P577
1999-06-01T00:00:00Z